Loading the next story…
Trump Removes FDA Commissioner Over Abortion Pill, Drug Approval Controversies — Nerve Wires | Nerve News
Skip to content
NERVE.NEWS
TodayStoriesWinners & LosersForecasts
Auto
Set the atmosphere

Scenery follows the section you’re exploring.

Subscribe

Explore Nerve

Desks & tools

The briefingStory hubsForecastsPrimersLiveblogWinners & LosersSearchSaved storiesDataWires

Categories

All categories →PoliticsEconomyForeign AffairsDefense & SecurityImmigration & BorderMedia & TechCulture & SocietyLaw & JusticeEducationDaily RoundupNewsroom
Subscribe to Nerve
Higher contrast, reduced visual effects, and simplified popups. Your choice is saved for this browser.
TodayBriefingSaved
Back to the briefingBriefingNERVE.NEWS
Home/Wires
WireMay 8, 2026 at 9:31 PM

Trump Removes FDA Commissioner Over Abortion Pill, Drug Approval Controversies

2 min left
0%

Reading controls

Reading Progress0%
Time remaining2 min
Total reading time2 min
Focus modeDims surrounding paragraphs

Editorial note

Comments

Previous

American Citizen Allegedly Proposes Greenland Annexation to Locals

Next

Court Rules Trump's Global 10% Tariff Illegal, Undermining Trade Policy

The Nerve Briefing

Power, culture, technology, and the world taking shape — when we publish. Subscribe →

NERVE.NEWS

A clear view of a changing world. Reporting and ideas with an American perspective.

Coverage

  • Economy
  • Foreign Affairs
  • Politics
  • Media & Tech
  • Culture & Society
  • Opinion
  • All sections
  • Wires
  • Forecasts

Resources

  • Primers
  • Policy Papers
  • Newsletter
  • RSS — All articles
  • RSS — Wires
  • Data
  • The briefing

Publication

  • Subscribe
  • Winners & Losers
  • Editorial Policy
  • About
© 2026 Nerve News. All rights reserved.
EthicsPrivacyAbout

President Trump has removed Dr. Makary from his position as FDA Commissioner following mounting controversies surrounding the agency's handling of abortion medication, drug approvals, and vaccine policies. The decision comes after prolonged clashes between Dr. Makary and anti-abortion groups, who have pushed for stricter regulations on abortion-inducing drugs.

Internal Tensions and Policy Disputes

Dr. Makary's tenure was marked by conflicts with other administration officials and advocacy groups critical of his approach to abortion medication. Anti-abortion organizations have accused the FDA of failing to enforce sufficient restrictions on these drugs, despite their widespread availability. Additionally, concerns were raised about the agency's drug approval process, which some argue prioritizes corporate interests over patient safety.

The FDA's role in drug regulation must align with the administration's commitment to protecting American lives and upholding ethical standards, a spokesman for the White House stated.

The administration has faced increasing pressure from conservative groups to take a firmer stance on abortion-related policies, particularly in the wake of recent Supreme Court rulings. Critics of Dr. Makary argue that his leadership failed to adequately address these concerns.

Impact on Vaccine Approvals

The FDA's vaccine approval process has also come under scrutiny, with accusations of inefficiency and opacity. Dr. Makary's departure raises questions about the future direction of the agency, particularly as the administration seeks to balance public health priorities with political and ethical considerations.

President Trump's decision underscores the administration's commitment to reshaping federal agencies to reflect its policy goals. The search for a new FDA Commissioner is expected to prioritize candidates who align with the administration's vision for healthcare regulation.